Equillium Stock Price, News & Analysis

Equillium, a clinical-stage biotechnology company, announced that its CEO Bruce Steel will present at the H.C. Wainwright Virtual BioConnect Conference on January 11, 2021, at 6:00 am EST. This presentation will focus on itolizumab, a treatment for severe autoimmune and inflammatory disorders. A webcast of the presentation will be accessible on the company’s website under the “Investors” section for 30 days following the event.

Equillium is dedicated to addressing high unmet medical needs in severe immuno-inflammatory diseases.

Equillium Strengthens Leadership with New Executive Appointments

Equillium, Inc. has announced key executive appointments, including Dolca Thomas, M.D., as executive vice president of research and development and chief medical officer. Dr. Thomas has extensive experience from Principia Biopharma and Roche. The company also appointed Michael Son, Ph.D., Nelson Lugo, and Michael Moore to key roles. These strategic hires aim to advance the development of itolizumab for severe autoimmune diseases, particularly acute graft versus host disease, with several critical readouts expected in the coming year.

Equillium, Inc. presented significant findings regarding itolizumab at the 2020 American Society of Hematology Annual Meeting. The study highlighted the drug's ability to suppress the activity of CD4 and CD8 T cells in patients with acute graft-versus-host disease (aGVHD). With no approved first-line therapies for aGVHD, itolizumab's mechanism of targeting the CD6-ALCAM pathway shows promise. Early data from the EQUATE Phase 1b study also supports its potential role in combination with steroids for treating aGVHD.

Equillium, Inc. (Nasdaq: EQ) has announced a virtual Investor and Analyst Day on December 4, 2020, from 9:30 a.m. to 12:00 p.m. ET, focusing on its leading drug candidate, itolizumab, a monoclonal antibody for treating severe autoimmune disorders, including aGVHD, lupus, and uncontrolled asthma. Key presentations will feature Dr. John Koreth from Dana-Farber Cancer Institute and the company's executives. Following presentations, there will be a Q&A session. A webcast will be available for 30 days on the company's Investor Relations website.

Equillium has announced it will not proceed with the EQUINOX Phase 3 clinical trial for itolizumab in COVID-19 patients, citing advancements in vaccines and treatments. CEO Bruce Steel emphasized the decision was strategic amidst a changing treatment landscape. Instead, the company will focus on expanding the itolizumab program for acute graft-versus-host disease, lupus, and asthma studies. The next pipeline updates are expected on December 4, coinciding with the Analyst Day.

Equillium, Inc. (Nasdaq: EQ) announced its Q3 2020 financial results, highlighting a net loss of $6.6 million, or $(0.31) per share, compared to a loss of $6.0 million, or $(0.35) per share in Q3 2019. The company reported a 100% response rate in cohort 3 and an 80% overall response rate in the EQUATE trial for severe aGVHD. It raised $53.0 million in net proceeds, boosting cash reserves to $90.5 million. Upcoming trials include the Phase 3 EQUINOX for COVID-19 patients, set to start this quarter, with initial data expected mid-2021.

Equillium, Inc. (Nasdaq: EQ) announced that CEO Bruce Steel and CMO Krishna Polu, M.D., will present at two investor conferences in November 2020. The first event is the Stifel 2020 Virtual Healthcare Conference on November 18 at 3:20 PM ET, followed by the Jefferies Virtual London Healthcare Conference on November 19 at 6:10 PM GMT. Live webcasts will be accessible on Equillium's website, with replays available for 30 days. The company is focused on developing its lead product, itolizumab, for various severe autoimmune diseases.

Equillium, a clinical-stage biotechnology company, released positive interim results from its Phase 1b EQUATE trial of itolizumab for treating acute graft-versus-host disease (aGVHD). The trial reported an 80% overall response rate across cohorts, with a 100% complete response in cohort 3. The firm plans to engage the FDA for expedited pathways for itolizumab, which has already received fast track and orphan drug designations. The complete response rate significantly exceeds standard steroid treatments, highlighting the potential of itolizumab as a life-saving therapy for aGVHD patients.

Equillium, Inc. (Nasdaq: EQ) announced promising data on its drug, itolizumab, for treating systemic lupus erythematosus and lupus nephritis. Presented at the 2020 American College of Rheumatology Virtual Convergence on November 7, the studies show that modulating the CD6-ALCAM pathway improved kidney and skin pathology in mouse models. Experts believe this pathway plays a crucial role in autoimmune diseases, suggesting that targeting it could yield effective treatments for lupus nephritis, a condition with no FDA-approved therapies.